- Chair: Helena Maltezou
- Co-Chair: Laura Talarico
- Speakers: Alfonso Rodriguez-Morales, Nicola Petrosillo, and Kenneth Linthicum
- December 13, 2022
Chikungunya is a mosquito borne viral disease caused by the Chikungunya virus (CHIKV), a Togaviridae virus, and is transmitted by Aedes mosquitoes. Clinical symptoms include acute onset of fever, debilitating joint and muscle pain, headache, nausea, and rash, potentially developing into long-term serious health impairments. Chikungunya virus causes clinical illness in 72 – 92% of infected human around 4 to 7 days after an infected mosquito bite. Complications resulting from the disease include visual, neurological, heart and gastrointestinal manifestations; fatalities have been reported in elderly people at higher risk.
Chikungunya outbreaks have been reported in Asia, Africa, the Americas and recently in Europe. Both the medical and economic burden are expected to grow as the CHIKV primary mosquito vectors continue their geographic spread Although there are some candidate vaccines in clinical trials none are licensed. Therefore, chikungunya shall remain a major public health threat.
- Chairs: Finghani Mphande-Nyasulu and Tatiana Pinto
- Speakers: Anon Srikiatkhachorn and Cristina Barroso Hofer
- December 8, 2022
According to the WHO, the incidence of dengue has increased considerably in recent decades. Dengue is now endemic in more than 100 countries in Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific. Asia bears about 70% of the global burden of dengue. There is no specific treatment for dengue. So far only one dengue vaccine CYD-TDV has been licensed for use. It is currently in use in about 20 countries globally. There are several candidate vaccines in different stages of development, some are currently in various stages of Clinical Trials. Several challenges have been faced in the development of the vaccines, some of which include the nature of the virus itself that has four serotypes and the immune response to the vaccine.
1. Amorim, Jaime Henrique et al. Dengue vaccines: where are we now and where we are going? The Lancet Infectious Diseases 2022. Volume 22, Issue 6, 756 – 757
2. Pinheiro-Michelsen JR, Souza SO, Santana IVR et al. Anti-dengue vaccines: from development to clinical trials. Front Immunol. 2020; 111252
3. Rose, Anuradha et al. Bioethics of establishing a CHIM model for dengue vaccine development. International Journal of Infectious Diseases 2019. Volume 84, S74 - S79
4. King, C.-C. Public health needs and challenges in influenza and dengue vaccines–Implications from epidemiological findings. International Journal of Infectious Diseases 2020 Volume 101, 324
- Chairs: Sophie Yacoub and Yeo Tsin Wen
- Speakers: Wanwisa Dejnirattisai, Nguyen Lam Vuong, and Damien Ming
- October 18, 2022
Dengue is the fastest spreading mosquito-borne viral disease; a distinction the WHO recognized when naming it a Top 10 threat to global health. Dengue is mainly spread by Aedes aegypti mosquitoes and, to a lesser extent, Aedes albopictus mosquitoes. It is caused by one of the four dengue serotypes, each of which can cause dengue fever or severe dengue. Dengue is pandemic-prone, and outbreaks are generally observed in tropical and subtropical areas. However, recent outbreaks have affected the continental United States and Europe. An estimated 40% of the world is at risk now lives with this threat. There has been a significant increase in number of dengue cases over the years, despite improvements in case management and a reduction in the Case Fatality Rate. Increased surveillance, better case management, innovative vector control, and diagnostics may improve control efforts globally.
- Moderator: Teresa L. Schraeder (USA)
- Panel: Gonzalo Bearman (USA)
- Panel: Paul Tambyah (Singapore)
- Panel: Mohammed Yahaya (NIgeria)
ISID Webinar: Infection Prevention and Control (IPC): Past, Present and Future
- Learn the importance of making IPC guidelines practical, relevant, and inclusive for all countries and all settings
- ISID Guide to Infection Control in the Healthcare Setting: Review the history and usage of this international resource now in its 6th edition
- Obtain information and knowledge from firsthand experiences of IPC successes in Nigeria
- Listen to discussion on how to improve understanding, compliance and practice of IPC globally
- Chairs: Dr. Sadia Shakoor (Pakistan), and Dr. Bethany Davies (Australia)
- Speakers: Dr. Ling-Shan Yu (Taiwan) and Dr. Jesus Rodriguez-Manzano (UK)
- September 20, 2022
Rapid diagnostic tests (RDTs) including point-of-care (POC) diagnostics, provide rapid diagnosis near the patient, often within accessible healthcare settings such as outpatient departments, screening sites and in primary care facilities. In contrast to conventional diagnostic assays, which typically rely upon specialised staff and centralised well equipped laboratories, POC tests are simple to use and can support timely, responsive infection management and disease surveillance. They are particularly important within low-resources settings where access to reliable power, cold-chain facilities and specialised laboratories may be limited. Emerging innovations in POC diagnostics, including sample preparation, molecular detection and data analytics offer further opportunities to improve performance, access and expand their role within infectious disease management.
- Speakers: Prof. Dimie Ogoina, M.D and Dr. David Hamer
- Facilitated by: Teresa L. Schraeder, M.D. (USA)
- Producer: Amador (Tino) Delamerced, BA (USA)
- August 3, 2022
Learning Objectives:
- Learn more about the latest surge of cases of Monkeypox
- Listen to discussion about the history of this DNA zoonotic virus
- Understand why public health officials are worried and the knowns/unknowns about this global emergency
- Hear analysis of problems with diagnosis, control, treatment, and prevention in different parts of the world
- Speaker: Dr. Bassem Zayed (Jordan)
- Moderators: Dr. Enrique Castro-Sanchez (United Kingdom) and Dr. Angel Desai (USA)
In this podcast, ISID Emerging Leaders Enrique Castro-Sanchez and Angel Desai speak with Dr. Bassem Zayed, Medical Officer, Infection Prevention and Control at the World Health Organization regarding challenges encountered during public health and humanitarian emergencies.
- Speaker: Anucha Apisarnthanarak, Professor, Thammasat University Hospital (Thailand)
- Facilitated by: Teresa L. Schraeder, M.D. (USA)
- Producer: Amador (Tino) Delamerced, BA (USA)
- July 12, 2022
MDR Organisms in the ICU
- MDR organisms of most concern in the ICU
- Pressures driving MDR in Thailand and elsewhere
- How Covid-19 impacted MDR
- Message about MDR from Asia
- Faculty: Shirani Chandrasiri (Sri Lanka), Esmita Charani (UK), Duminda Samarasinghe (Sri Lanka), Seif Al-Abri (Oman)
- June 21, 2022
This session will review some of the AMR challenges faced in low- and middle-income countries. The increase in resistance of microbes to antimicrobials is outpaced by the development of effective and safe antimicrobial agents. AMR has both health and economic impacts, particularly in low- and middle-income countries. In low resource settings, there is low availability and high costs of some of the laboratory tests routinely conducted in high income countries to manage AMR. The case we shall present addresses Multisystem Inflammatory Syndrome in Children (MIS-C) which has been reported worldwide with temporal association with COVID-19. MIS-C is a post-infectious multi-organ inflammatory consequence of such infection. It is a heterogeneous disease entity where prominent cardiovascular complications, particularly myocardial and coronary artery involvement is recognized.
